Pharmacological strategies for clozapine-induced hypersalivation: Treatment with botulinum toxin B in one patient and review of the literature;Therapie der clozapin-induzierten hypersalivation mit botulinum-toxin B

Nervenarzt

Volumn 76, Issue 2, 2005, Pages 205-208

  Kahl, K G ^a,b   Trillenberg, P ^a   Kordon, A ^a   Lencer, R ^a   Klein, C ^a   Hagenah, J ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b Klin F Psychiat Psychotherapie   (Germany)

Author keywords

Botulinum toxin; Clozapin; Hypersalivation; Schizophrenia

Indexed keywords

ATROPINE; BOTULINUM TOXIN B; CLOZAPINE; PIRENZEPINE;

ADULT; ANAMNESIS; ARTICLE; AUDITORY HALLUCINATION; CASE REPORT; CLINICAL FEATURE; HUMAN; HYPERSALIVATION; LABORATORY TEST; MALE; PARANOID SCHIZOPHRENIA;

ADULT; BOTULINUM TOXINS; CLOZAPINE; HUMANS; MALE; MUSCARINIC ANTAGONISTS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; SCHIZOPHRENIA; SIALORRHEA;

EID: 14544308876     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-004-1800-x     Document Type: Article

References (30)

1. Antonello C, Tessier P (1999) Clozapine and siallorrhea: a new intervention for this bothersome and potentially dangerous side effect. J Psychiatry Neurosci 24:250
2. Bai Y-M, Lin C-C, Chen J-Y et al. (2001) Therapeutic effect of pirenzipine for clozapine-induced hypersalivation: a randomized, double-blind, placebo-controlled, cross-over study. J Clin Psychopharmacol 6:608-611
3. Breier A, Buchanan RW, Kirkpatrick B et al. (1995) Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 151:20-26
4. Brodkin ES, Pelton GH, Price LH (1996) Treatment of clozapine-induced parotid gland swelling. Am J Psychiatry 153:445
5. Calderon J, Rubin E, Sobota WL (2000) Potential use of ipatropium bromide for the treatment of clozapine-induced hypersalivation: a preliminary report. Int Clin Psychopharmacol 15:49-52
6. Comley C, Galletly C, Ash D (2000) Use of atropine eye drops for clozapine induced hypersalivation. Aust NZ J Psychiatry 34:1033-1034
7. Copp PJ, Lament R, Tennent TG (1991) Amitryptiline in clozapine-induced sialorrhea. Br J Psychiatry 159:166
8. Corrigan FM, MacDonald S, Reynolds GP (1995) Clozapine-induced hypersalivation and the alpha-2 adrenoceptor. Br J Psychiatry 167:412
9. Davydov L, Botts SR (2000) Clozapine-induced hypersalivation. Ann Pharmacother 34:662-665
10. Ellies M, Laskawi R, Rohrbach-Volland S et al. (2003) Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies. J Oral Maxillofac Surg 61:454-457
11. Fritze J, Elliger T (1995) Pirenzipine for clozapine-induced hypersalivation. Lancet 346:1034
12. Giess R, Naumann M, Werner E et al. (2000) Injections of botulinum toxin A into the salivary glands improve sialorrhea in amyotrophic lateral sclerosis. J Neural Neurosurg Psychiatry 69:121-123
13. Grabowski J (1992) Clonidine treatment of clozapine-inuced hypersalivation. J Clin Psychopharmacol 12:69-70
14. Hinkes R, Quesada TV, Currier MB et al. (1996) Aspiration pneumonia possibly secondary to clozapine-induced sialorrhea. J Clin Psychopharmacol 16:462-463
15. Kahl KG, Hagenah J, Zapf S et al. (2004) Botulinum toxin as an effective treatment of clozapin-induced hypersalivation. Psychopharmacology 173:229-230
16. Mancini F, Zangaglia R, Cristina S et al. (2003) Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 18:685-688
17. McCarthy RH, Terkelsen KG (1994) Esophageal dysfunction in two patients after clozapine treatment. J Clin Psychopharmacol 14:281-283
18. Meltzer HY, Alphs L, Green AI et al. (2003) International Suicide Prevention Trial Study Group: Clocapine treatment for suicidality in schizophrenia: International suicide prevention trial (InterSePT). Arch Gen Psychiatry 60:82-91
19. Miller DD (2000) Review and managment of clozapine side effects. J Clin Psychiatry 61 (Suppl 8):14-17
20. Naber D, Leppig M, Grohmann R et al. (1989) Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia - a retrospective study of 387 patients. Psychopharmacology 99:S73-S76
21. Ondo WG, Hunter C, Moore W (2004) A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 62:37-40
22. Pal PK, Calne DB, Calne S et al. (2000) Botulinum toxin A as treatment for drooling saliva in PD. Neurology 54:244-247
23. Perkins DO, McClure RK (1989) Hypersalivation coincident with olanzapine treatment. Am J Psychiatry 155:993-994
24. Porta M, Gamba M, Bertacchi G et al. (2001) Treatment of sialorrhea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders. J Neurol Neurosurg Psychiatry 70:538-540
25. Reinstein MJ, Sirotovskaya LA, Chasanov MA et al. (1999) Comparative efficacy and tolerability of benztropin and terazosin in the treatment of hypersalivation secondary to clozapine. Clin Drug Investig 17:97-102
26. Robinson D, Fenn H, Yesavage J (1995) Possible association of parotitis with clozapine. Am J Psychiatry 152:297-298
27. Rogers DP, Shramko JK (2000) Therapeutic options in the treatment of clozapine-induced sialorrhea. Pharmacotherapy 20:1092-1095
28. Schneider B, Weigmann H, Hiemke C et al. (2004). Reduction of clozapine-induced hypersalivation by pirenzipine is safe. Pharmacopsychiatry 37:43-45
29. Spivak B, Adlersberg S, Rosen L et al. (1997) Trihexphenidyl treatment of clozapine induced hypersalivation. Int Clin Psychopharmacol 12:213-215
30. Spivak B, Shabash E, Sheitman B et al. (2003) The effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. J Clin Psychiatry 64:755-760